Attenuation and Stability of CHIKV-NoLS, a Live-Attenuated Chikungunya Virus Vaccine Candidate

被引:11
|
作者
Abeyratne, Eranga [1 ]
Freitas, Joseph R. [1 ]
Zaid, Ali [1 ]
Mahalingam, Suresh [1 ]
Taylor, Adam [1 ]
机构
[1] Griffith Univ, Inst Glyc, Emerging Viruses & Inflammat Res Grp, Gold Coast, Qld 4222, Australia
基金
英国医学研究理事会;
关键词
alphavirus; chikungunya virus; live-attenuated; vaccine; preclinical; BURDEN; EPIDEMIOLOGY; INFECTION; DISEASE;
D O I
10.3390/vaccines7010002
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Our previous investigation of the nucleolar localisation sequence (NoLS) of chikungunya virus (CHIKV) capsid protein demonstrated the role of capsid in CHIKV virulence. Mutating the NoLS of capsid in CHIKV led to the development of a unique live-attenuated CHIKV vaccine candidate, termed CHIKV-NoLS. CHIKV-NoLS-immunised mice developed long-term immunity from CHIKV infection after a single dose. To further evaluate CHIKV-NoLS attenuation and suitability as a vaccine, we examined the footpad of inoculated mice for underlying CHIKV-NoLS-induced immunopathology by histological and flow cytometric analysis. In comparison to CHIKV-WT-infected mice, CHIKV-NoLS-inoculated mice exhibited minimal inflammation and tissue damage. To examine the stability of attenuation, the plaque phenotype and replication kinetics of CHIKV-NoLS were determined following extended in vitro passage. The average plaque size of CHIKV-NoLS remained notably smaller than CHIKV-WT after extended passage and attenuated replication was maintained. To examine thermostability, CHIKV-NoLS was stored at 21 degrees C, 4 degrees C, -20 degrees C and -80 degrees C and infectious CHIKV-NoLS quantified up to 84 days. The infectious titre of CHIKV-NoLS remains stable after 56 days when stored at either -20 degrees C or -80 degrees C. Interestingly, unlike CHIKV-WT, the infectious titre of CHIKV-NoLS is not sensitive to freeze thaw cycles. These data further demonstrate preclinical safety and stability of CHIKV-NoLS.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] Liposomal Delivery of the RNA Genome of a Live-Attenuated Chikungunya Virus Vaccine Candidate Provides Local, but Not Systemic Protection After One Dose
    Abeyratne, Eranga
    Tharmarajah, Kothila
    Freitas, Joseph R.
    Mostafavi, Helen
    Mahalingam, Suresh
    Zaid, Ali
    Zaman, Mehfuz
    Taylor, Adam
    FRONTIERS IN IMMUNOLOGY, 2020, 11
  • [22] Genetic stability of live-attenuated Zika vaccine candidates
    Muruato, Antonio E.
    Shan, Chao
    Fontes-Garfias, Camila R.
    Liu, Yang
    Cao, Zengguo
    Gao, Qiang
    Weaver, Scott C.
    Shi, Pei-Yong
    ANTIVIRAL RESEARCH, 2019, 171
  • [23] Live-attenuated CHIKV vaccine with rearranged genome replicates in vitro and induces immune response in mice
    Tretyakova, Irina
    Joh, Joongho
    Gearon, Mary
    Kraenzle, Jennifer
    Goedeker, Sidney
    Pignataro, Ava
    Alejandro, Brian
    Lukashevich, Igor S.
    Chung, Donghoon
    Pushko, Peter
    PLOS NEGLECTED TROPICAL DISEASES, 2024, 18 (04):
  • [24] Live-attenuated varicella vaccine
    Gershon, AA
    INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, 2001, 15 (01) : 65 - +
  • [25] Analysis of Humoral Immune Responses in Chikungunya Virus (CHIKV)-Infected Patients and Individuals Vaccinated With a Candidate CHIKV Vaccine
    Henss, Lisa
    Yue, Constanze
    Von Rhein, Christine
    Tschismarov, Roland
    Lewis-Ximenez, Lia Laura
    Doelle, Albert
    Baylis, Sally A.
    Schnierle, Barbara S.
    JOURNAL OF INFECTIOUS DISEASES, 2020, 221 (10): : 1713 - 1723
  • [26] Assessing the Diversity and Stability of Cellular Immunity Generated in Response to the Candidate Live-Attenuated Dengue Virus Vaccine TAK-003
    Waickman, Adam T.
    Friberg, Heather
    Gargulak, Morgan
    Kong, Amanda
    Polhemus, Mark
    Endy, Timothy
    Thomas, Stephen J.
    Jarman, Richard G.
    Currier, Jeffrey R.
    FRONTIERS IN IMMUNOLOGY, 2019, 10 : 1778
  • [27] Immunogenicity and safety of a live-attenuated SARS-CoV-2 vaccine candidate based on multiple attenuation mechanisms
    Okutani, Mie Suzuki
    Okamura, Shinya
    Gis, Tang
    Sasaki, Hitomi
    Lee, Suni
    Kashiwabara, Akiho
    Goto, Simon
    Matsumoto, Mai
    Yamawaki, Mayuko
    Miyazaki, Toshiaki
    Nakagawa, Tatsuya
    Ikawa, Masahito
    Kamitani, Wataru
    Takekawa, Shiro
    Yamanishi, Koichi
    Ebina, Hirotaka
    ELIFE, 2025, 13
  • [28] Live-attenuated RNA hybrid vaccine technology provides single-dose protection against Chikungunya virus
    Voigt, Emily A.
    Fuerte-Stone, Jasmine
    Granger, Brian
    Archer, Jacob
    Van Hoeven, Neal
    MOLECULAR THERAPY, 2021, 29 (09) : 2782 - 2793
  • [29] Development of a novel equine influenza virus live-attenuated vaccine
    Rodriguez, Laura
    Reedy, Stephanie
    Nogales, Aitor
    Murcia, Pablo R.
    Chambers, Thomas M.
    Martinez-Sobrido, Luis
    VIROLOGY, 2018, 516 : 76 - 85
  • [30] Development of Attenuated and Immunogenic Live-attenuated Respiratory Syncytial Virus Vaccine Candidates
    Hornung, Sandra L.
    Tran, Kim C.
    Teng, Michael N.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2019, 143 (02) : AB120 - AB120